The Intelligent Manipulator for the Microscopic World
Cell manipulation is a fundamental and widely applicable key step in life science. However, traditional microinjection, gene editing, and single-cell extraction remain constrained by challenges such as low efficiency, high damage rates, strong reliance on operator expertise, and insufficient precision.
ScimaX AI, the AI-Controlled Single Cell In-suit Manipulator platform independently developed by Sinboda, breaks traditional limitations with a disruptive architecture. It integrally combines core technologies including high-end optical imaging, AI algorithms, and collaborative robotic manipulators, reconstructing the entire workflow from single-cell extraction, injection, analysis. This ushers cell manipulation into a new intelligent paradigm of "Algorithm × Mechanical Synergy" for precise control. The platform is compatible with adherent and suspension cells, small and large cells (oocytes/embryos), and live organisms (e.g., nematodes). As an intelligent, mechanical, and fully integrated cell manipulation platform, ScimaX AI provides a revolutionary universal technology foundation for gene editing, cell therapy, and rare cell clinical research.
The ScimaX AI offers a full-process solution—extraction, injection, sorting, and analysis—for diverse cell types and manipulation scenarios, featuring broad-spectrum adaptability. Based on this platform, we have developed a product matrix for different applications: Oocyte Microinjection Edition, Assisted Reproduction Edition, Small Cell Gene Editing Edition, Single-Arm Precision Picking Edition, High-Content Micro-Nano Manipulation Edition, etc., using specialized editions to precisely match diverse scenarios.
Through the deep integration of AI and life science, ScimaX AI is redefining the future of cell manipulation, truly enabling intelligent, standardized, and engineerable cell control.
ScimaX is independently developed and fully integrates core technologies such as optical imaging, nanoscale precision robotic arms, and artificial intelligence algorithms.
Four Major Injection Systems: Hydraulic injection pump, picoliter-scale pneumatic pulse system, piezoelectric membrane penetration, and electrical pulse injection system, meeting diverse operational needs.
Self-Developed Consumables Forming a Closed Loop: In-house production of needle consumables with aperture sizes ranging from 200 nm to 300 μm, catering to the demands of various scenarios.
Automated Image Recognition: Built a high-quality image database for multi-species, multi-type biological samples (human/animal oocytes, embryos, sperm; nematodes, zebrafish; adherent cells like HEK293/HeLa/CHO; stem cells, neurons, etc.). Develops lightweight, task-oriented models based on operational targets for fast, accurate, and robust sample identification and annotation.
Automated Workflow: Enables high-throughput automated execution of experimental processes like injection, dissociation, picking, and cross-environment transfer via point-and-click interaction; standardized optimal parameter sets for different cell types × operation scenarios ensure consistency, reproducibility, and traceability of results.
Diverse Sample Compatibility: Compatible with various biological samples including adherent cells, suspension cells, oocytes, embryos, nematodes, and zebrafish.
Full-Scenario Cell Operation Coverage: Supports key processes such as pronuclear/cytoplasmic injection, Intracytoplasmic Sperm Injection (ICSI), ES cell-embryo chimera construction, and embryonic nuclear transfer.
Highly Scalable Self-Developed Imaging System: Self-developed imaging modules support widefield brightfield, Hoffman modulation contrast, multi-color fluorescence, TIRF, confocal/spinning disk confocal, light-sheet 3D real-time fluorescence, etc.; features What-You-See-Is-What-You-Get image-based in-situ operation and can be flexibly configured to meet imaging needs at different depth and resolution levels.
Professional-Focused Product Matrix: Extends from a unified technology platform to form a multi-product matrix, precisely adapting to different scenarios and operational needs—Oocyte Microinjection Edition, Assisted Reproduction Edition, Small Cell Gene Editing Edition, Single-Arm Precision Picking Edition, High-Content Imaging Edition, 3D Imaging Edition, etc.; specialized editions enable precise matching with diverse applications and highly efficient deployment.
Customizable Configuration List: Freedom to select imaging, operation, and software functions based on customer requirements; both hardware and software support modular combination and custom development, covering application needs across different levels and scenarios.
In Gene Editing Scenarios:
· For large cells (e.g., oocytes) and live models (e.g., nematodes, zebrafish), ScimaX AI replaces manual operations with automated microinjection, streamlining complex, experience-dependent processes into one-click, standardized procedures, significantly improving gene editing positive rates, consistency, and reproducibility.
· For gene delivery into small cells, ScimaX AI replaces traditional electroporation and limited dilution with an integrated process of precision injection and intelligent selection, addressing pain points like high randomness, significant damage, low efficiency, long cycles, and carrier limitations, thereby achieving precise, efficient, non-destructive, and broad-spectrum "universal transfection".
In the Field of Cell Sorting:
While flow cytometry offers high-throughput advantages, it struggles with the precise screening of rare cells and functional cells. The ScimaX AI platform provides a fundamental breakthrough here——
· Rare Cell Extraction: Enables high-precision screening and isolation of specific cells from low-abundance samples, providing high-purity sample sources for early disease screening, functional studies, and cell therapy.
· Target Functional Cell Screening: Achieves precise screening of target cells based on imaging and phenotypic characteristics, supporting functional-level discrimination. For instance, for cell therapy, real-time interactions between immune cells and tumor cells can be utilized to screen for immune cells with specific killing/response capabilities, providing new tools for gene and cell therapy.
